JP2002516566A - 金属介在セリンプロテアーゼインヒビター - Google Patents
金属介在セリンプロテアーゼインヒビターInfo
- Publication number
- JP2002516566A JP2002516566A JP52360898A JP52360898A JP2002516566A JP 2002516566 A JP2002516566 A JP 2002516566A JP 52360898 A JP52360898 A JP 52360898A JP 52360898 A JP52360898 A JP 52360898A JP 2002516566 A JP2002516566 A JP 2002516566A
- Authority
- JP
- Japan
- Prior art keywords
- serine protease
- divalent metal
- metal cation
- zinc
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003001 serine protease inhibitor Substances 0.000 title claims abstract description 32
- 229940122055 Serine protease inhibitor Drugs 0.000 title claims abstract description 21
- 101710102218 Serine protease inhibitor Proteins 0.000 title claims abstract description 18
- 229910052751 metal Inorganic materials 0.000 title claims description 118
- 239000002184 metal Substances 0.000 title claims description 118
- 230000001404 mediated effect Effects 0.000 title description 3
- 150000001768 cations Chemical class 0.000 claims abstract description 116
- 102000012479 Serine Proteases Human genes 0.000 claims abstract description 103
- 108010022999 Serine Proteases Proteins 0.000 claims abstract description 103
- 150000001875 compounds Chemical class 0.000 claims abstract description 97
- 238000000034 method Methods 0.000 claims abstract description 89
- 239000003112 inhibitor Substances 0.000 claims abstract description 51
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 46
- 230000005764 inhibitory process Effects 0.000 claims abstract description 21
- 239000011701 zinc Substances 0.000 claims description 76
- 229910052725 zinc Inorganic materials 0.000 claims description 73
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 70
- 239000012588 trypsin Substances 0.000 claims description 47
- -1 polycyclic hydrocarbon Chemical class 0.000 claims description 45
- 125000005842 heteroatom Chemical group 0.000 claims description 37
- 238000003556 assay Methods 0.000 claims description 33
- 239000004365 Protease Substances 0.000 claims description 30
- 102000035195 Peptidases Human genes 0.000 claims description 29
- 108091005804 Peptidases Proteins 0.000 claims description 29
- 108090000631 Trypsin Proteins 0.000 claims description 29
- 102000004142 Trypsin Human genes 0.000 claims description 29
- 125000004429 atom Chemical group 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 125000004432 carbon atom Chemical group C* 0.000 claims description 19
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 17
- 102000003827 Plasma Kallikrein Human genes 0.000 claims description 16
- 108090000113 Plasma Kallikrein Proteins 0.000 claims description 16
- 108010074860 Factor Xa Proteins 0.000 claims description 15
- 108090000190 Thrombin Proteins 0.000 claims description 15
- 229940088598 enzyme Drugs 0.000 claims description 15
- 229960004072 thrombin Drugs 0.000 claims description 15
- 108010054265 Factor VIIa Proteins 0.000 claims description 14
- 108010088842 Fibrinolysin Proteins 0.000 claims description 14
- 108060005989 Tryptase Proteins 0.000 claims description 14
- 102000001400 Tryptase Human genes 0.000 claims description 14
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 14
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 229940012414 factor viia Drugs 0.000 claims description 14
- 229940012957 plasmin Drugs 0.000 claims description 14
- 229960005356 urokinase Drugs 0.000 claims description 14
- 241000701022 Cytomegalovirus Species 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 101710176219 Kallikrein-1 Proteins 0.000 claims description 13
- 101800004937 Protein C Proteins 0.000 claims description 13
- 101800001700 Saposin-D Proteins 0.000 claims description 13
- 102000006635 beta-lactamase Human genes 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 229960000856 protein c Drugs 0.000 claims description 13
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 12
- 108090000204 Dipeptidase 1 Proteins 0.000 claims description 12
- 108010048049 Factor IXa Proteins 0.000 claims description 12
- 229960001322 trypsin Drugs 0.000 claims description 12
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 11
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 11
- 108010067035 Pancrelipase Proteins 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 10
- 230000003993 interaction Effects 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000005647 linker group Chemical group 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 125000003282 alkyl amino group Chemical group 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 230000009920 chelation Effects 0.000 claims description 8
- 230000007170 pathology Effects 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical group OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 7
- 150000001721 carbon Chemical group 0.000 claims description 7
- 229910017052 cobalt Inorganic materials 0.000 claims description 7
- 239000010941 cobalt Substances 0.000 claims description 7
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 241001061127 Thione Species 0.000 claims description 5
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 5
- 125000002091 cationic group Chemical group 0.000 claims description 5
- 239000013522 chelant Substances 0.000 claims description 5
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 5
- 239000003352 sequestering agent Substances 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 239000004215 Carbon black (E152) Substances 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 3
- 125000005549 heteroarylene group Chemical group 0.000 claims description 3
- 229930195733 hydrocarbon Natural products 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 claims 10
- 102000057032 Tissue Kallikreins Human genes 0.000 claims 10
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 2
- DSPHFASHOJAOKN-UHFFFAOYSA-N 1-[(7-oxobenzo[a]phenalen-2-yl)amino]anthracene-9,10-dione Chemical compound C1=CC2=CC(NC3=C4C(=O)C5=CC=CC=C5C(C4=CC=C3)=O)=CC(C=3C(=CC=CC=3)C3=O)=C2C3=C1 DSPHFASHOJAOKN-UHFFFAOYSA-N 0.000 claims 1
- 102000004317 Lyases Human genes 0.000 claims 1
- 108090000856 Lyases Proteins 0.000 claims 1
- JOUBJFDKPCGZNJ-UHFFFAOYSA-N N1C(=NC=C1)CC=1NC2=C(N1)C=CC=C2 Chemical compound N1C(=NC=C1)CC=1NC2=C(N1)C=CC=C2 JOUBJFDKPCGZNJ-UHFFFAOYSA-N 0.000 claims 1
- 101800005085 Serine protease inhibitor A Proteins 0.000 claims 1
- 238000002955 isolation Methods 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 33
- 239000000203 mixture Substances 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 229940125904 compound 1 Drugs 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 239000012911 assay medium Substances 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 239000013078 crystal Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 125000000732 arylene group Chemical group 0.000 description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102100024539 Chymase Human genes 0.000 description 4
- 108090000227 Chymases Proteins 0.000 description 4
- 108090000317 Chymotrypsin Proteins 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 229960002376 chymotrypsin Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102100038297 Kallikrein-1 Human genes 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102400000827 Saposin-D Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010028275 Leukocyte Elastase Proteins 0.000 description 2
- 239000007987 MES buffer Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- DTKAXPPJFHHRHO-UHFFFAOYSA-N [2-[(6-methyl-1h-benzimidazol-2-yl)methyl]-3h-benzimidazol-5-yl]methanamine Chemical compound C1=C(CN)C=C2NC(CC3=NC4=CC=C(C=C4N3)C)=NC2=C1 DTKAXPPJFHHRHO-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000000320 amidine group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- KWMLJOLKUYYJFJ-GASJEMHNSA-N (2xi)-D-gluco-heptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C(O)=O KWMLJOLKUYYJFJ-GASJEMHNSA-N 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 125000005668 1,2-anthracenylene group Chemical group [H]C1=C([H])C2=C(C([H])=C1[H])C([H])=C1C(C([H])=C([H])C([*:2])=C1[*:1])=C2[H] 0.000 description 1
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 description 1
- 125000005669 1,3-anthracenylene group Chemical group [H]C1=C([H])C2=C(C([H])=C1[H])C([H])=C1C([*:1])=C([H])C([*:2])=C([H])C1=C2[H] 0.000 description 1
- 125000005838 1,3-cyclopentylene group Chemical group [H]C1([H])C([H])([H])C([H])([*:2])C([H])([H])C1([H])[*:1] 0.000 description 1
- WRSMGOKXDRBCRQ-UHFFFAOYSA-N 1-amino-1-carbamimidoylguanidine Chemical compound NC(=N)N(N)C(N)=N WRSMGOKXDRBCRQ-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical group CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- VIODAJWKMAMYPF-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylmethyl)-3h-benzimidazole-5-carboxylic acid Chemical compound C1=CC=C2NC(CC3=NC4=CC=C(C=C4N3)C(=O)O)=NC2=C1 VIODAJWKMAMYPF-UHFFFAOYSA-N 0.000 description 1
- KWKNRKYEYMYXDH-UHFFFAOYSA-N 2-(2-aminophenyl)-3h-benzimidazole-5-carboximidamide Chemical compound N1C2=CC(C(=N)N)=CC=C2N=C1C1=CC=CC=C1N KWKNRKYEYMYXDH-UHFFFAOYSA-N 0.000 description 1
- DGQZUPHFLBFALV-UHFFFAOYSA-N 2-(2-sulfanylphenyl)-3H-benzimidazole-5-carboximidamide Chemical compound N1C2=CC(C(=N)N)=CC=C2N=C1C1=CC=CC=C1S DGQZUPHFLBFALV-UHFFFAOYSA-N 0.000 description 1
- MHSMXTLGYPLSJM-UHFFFAOYSA-N 2-(pyridin-2-ylmethyl)-3h-benzimidazole-5-carboximidamide Chemical compound N1C2=CC(C(=N)N)=CC=C2N=C1CC1=CC=CC=N1 MHSMXTLGYPLSJM-UHFFFAOYSA-N 0.000 description 1
- IXEHZMUOBBZTNR-UHFFFAOYSA-N 2-[2-(1h-benzimidazol-2-yl)ethyl]-1h-benzimidazole Chemical compound C1=CC=C2NC(CCC=3NC4=CC=CC=C4N=3)=NC2=C1 IXEHZMUOBBZTNR-UHFFFAOYSA-N 0.000 description 1
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- ICDCECQARHLULZ-UHFFFAOYSA-N 2-isoquinolin-1-yl-3h-benzimidazole-5-carboximidamide Chemical compound C1=CC=C2C(C3=NC4=CC=C(C=C4N3)C(=N)N)=NC=CC2=C1 ICDCECQARHLULZ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- RVIFTTGMSLOWED-UHFFFAOYSA-N 2-pyridin-2-yl-3h-benzimidazole-5-carboximidamide Chemical compound N1C2=CC(C(=N)N)=CC=C2N=C1C1=CC=CC=N1 RVIFTTGMSLOWED-UHFFFAOYSA-N 0.000 description 1
- QFXZSLFLWAJDDV-UHFFFAOYSA-N 2-quinolin-8-yl-3h-benzimidazole-5-carboximidamide Chemical compound C1=CN=C2C(C3=NC4=CC=C(C=C4N3)C(=N)N)=CC=CC2=C1 QFXZSLFLWAJDDV-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- MLMQPDHYNJCQAO-UHFFFAOYSA-N 3,3-dimethylbutyric acid Chemical compound CC(C)(C)CC(O)=O MLMQPDHYNJCQAO-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 241001290610 Abildgaardia Species 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108020004256 Beta-lactamase Proteins 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 108090000617 Cathepsin G Proteins 0.000 description 1
- 102100025975 Cathepsin G Human genes 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000856199 Homo sapiens Chymotrypsin-like protease CTRL-1 Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102100027612 Kallikrein-11 Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000152158 Mesene Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 102100033174 Neutrophil elastase Human genes 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IRGBGRUKNLKOLZ-UHFFFAOYSA-N O-(methylideneamino)sulfanylhydroxylamine Chemical group NOSN=C IRGBGRUKNLKOLZ-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000208474 Protea Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 101000619156 Streptomyces griseus Streptogrisin-A Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 101710152431 Trypsin-like protease Proteins 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 108010055615 Zein Proteins 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- PZVJWWRDMGPXRH-UHFFFAOYSA-N [2-(1h-benzimidazol-2-ylmethyl)-3h-benzimidazol-5-yl]methanamine Chemical compound C1=CC=C2NC(CC3=NC4=CC=C(C=C4N3)CN)=NC2=C1 PZVJWWRDMGPXRH-UHFFFAOYSA-N 0.000 description 1
- GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical compound [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001409 amidines Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- ORTYMGHCFWKXHO-UHFFFAOYSA-N diethadione Chemical compound CCC1(CC)COC(=O)NC1=O ORTYMGHCFWKXHO-UHFFFAOYSA-N 0.000 description 1
- 229960003675 diethadione Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical group OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002901 elastaselike Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 125000005394 methallyl group Chemical group 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 235000019488 nut oil Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003147 proline derivatives Chemical class 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000003499 redwood Nutrition 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 108010036927 trypsin-like serine protease Proteins 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
- G01N2333/04—Varicella-zoster virus
- G01N2333/045—Cytomegalovirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/976—Trypsin; Chymotrypsin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Detergent Compositions (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.化合物のセリンプロテアーゼ阻害活性を測定するための方法であって、前 記化合物と、媒体に存在する二価の金属カチオンを有する媒体中のセリンプロテ アーゼとを接触せしめることを含んで成り、ここで前記カチオンが前記化合物と の相互作用のための能力、及びそれにより、前記化合物が有するいづれかのセリ ンプロテアーゼ阻害活性を強化する能力を有し、そして前記媒体中の二価の金属 カチオンの濃度がいづれかのそのような相互作用を引き起こすのに十分なレベル まで変更されることを特徴とする方法。 2.前記二価の金属カチオンが、亜鉛及びコバルトから成る群から選択される 請求の範囲第1項記載の方法。 3.前記二価の金属カチオンが亜鉛であり、そして前記亜鉛の濃度が少なくと も0.1μMに変更される請求の範囲第2項記載の方法。 4.前記亜鉛の濃度が少なくとも1μMに変更される請求の範囲第3項記載の 方法。 5.前記亜鉛の濃度が少なくとも100μMに変更される請求の範囲第4項記載 の方法。 6.前記セリンプロテアーゼが、活性化されたプロテインC、チマーゼ、キモ トリプシン、サイトメガロウィルスプロテアーゼ、エラスターゼ、第VIIa因子 、第IXa因子、第Xa因子、血漿カリクレイン、組織カリクレイン、β−ラクタ マーゼ、プラスミン、トロンビン、トリプシン、トリプターゼ及びウロキナーゼ から成る群から選択される請求の範囲第1項記載の方法。 7.前記セリンプロテアーゼが前記二価の金属カチオンによる阻害に対して敏 感であり、前記方法が、相互作用を引き起こすように 交換平衡により十分な二価の金属カチオンを供給しながら、前記セリンプロテア ーゼが二価の金属カチオンの存在により実質的に阻害されない程度まで、前記二 価の金属カチオンの自由濃度を減じることができる媒体に存在する金属緩衝剤を 有する媒体中で、前記化合物とセリンプロテアーゼとを接触せしめることをさら に含んで成る請求の範囲第1項記載の方法。 8.前記二価の金属カチオンが亜鉛であり、前記亜鉛の濃度が少なくとも0.1 μMに変更され、そして前記金属緩衝剤がオキサレートである請求の範囲第7項 記載の方法。 9.セリンプロテアーゼインヒビターの阻害活性が二価の金属カチオンの存在 により強化されるかどうかを決定するための方法であって; (a)前記インヒビターによるセリンプロテアーゼの阻害についてアッセイし 、ここで前記アッセイは解離された二価金属カチオンを実質的に欠いている媒体 において実施され;そして (b)前記化合物によるセリンプロテアーゼの阻害について、段階(a)に使 用されるアッセイ条件に対して実質的に同等な条件下でアッセイし、但し、段階 (b)において実施されるアッセイは有効濃度の二価金属カチオンを含む媒体中 で実施されることを含んで成り; ここで段階(b)により測定される場合の化合物の阻害活性が、段階(a)に より測定される場合の化合物の阻害活性よりも有意に高いことを特徴とする方法 。 10.前記二価の金属カチオンが亜鉛及びコバルトから成る群から選択され、そ して前記二価の金属カチオンが、カチオン金属イオン封鎖剤の存在により段階( a)に使用される媒体から除去される請求の範囲第9項記載の方法。 11.前記段階(b)に使用される媒体における亜鉛の濃度が、少なくとも0.1 μMに変更される請求の範囲第10項記載の方法・ 12.前記カチオン金属イオン封鎖剤がEDTAである請求の範囲第11項記載の方法 。 13.前記段階(b)に使用される媒体における亜鉛の濃度が、少なくとも1μ Mに変更される請求の範囲第12項記載の方法。 14.前記段階(b)に使用される媒体における亜鉛の濃度が、少なくとも100 μMに変更される請求の範囲第13項記載の方法。 15.前記二価の金属カチオンが亜鉛であり、そして前記段階(b)により測定 される場合の化合物の阻害活性が、前記段階(a)により測定される場合の化合 物の阻害活性よりも少なくとも10倍高い請求の範囲第14項記載の方法。 16.前記段階(b)により測定される場合の化合物の阻害活性が、前記段階( a)により測定される場合の化合物の阻害活性よりも少なくとも100倍高い請求 の範囲第15項記載の方法。 17.前記段階(b)により測定される場合の化合物の阻害活性が、前記段階( a)により測定される場合の化合物の阻害活性よりも少なくとも1000倍高い請求 の範囲第16項記載の方法。 18.前記セリンプロテアーゼが前記二価の金属カチオンによる阻害に対して敏 感であり、前記方法が、金属カチオンとの二元錯体又は金属カチオン及びプロテ アーゼとの三元錯体中に前記化合物のいづれか又はすべてを有するように平衡交 換により十分な二価の金属カチオンを供給しながら、前記セリンプロテアーゼが 二価の金属カチオンにより実質的に阻害されない程度まで、前記二価の金属カチ オンの自由濃度を減じることができる金属緩衝剤を含む媒体中で、段階(a)及 び(b)において行なわれるアッセイを実施することをさらに含んで成る請求の 範囲第11項記載の方法。 19.前記金属緩衝剤がオキサレートである請求の範囲第18項記載の方法。 20.前記セリンプロテアーゼが、活性化されたプロテインC、チマーゼ、キモ トリプシン、サイトメガロウィルスプロテアーゼ、エラスターゼ、第VIIa因子 、第IXa因子、第Xa因子、血漿カリクレイン、組織カリクレイン、β−ラクタ マーゼ、プラスミン、トロンビン、トリプシン、トリプターゼ及びウロキナーゼ から成る群から選択される請求の範囲第9項記載の方法。 21.セリンプロテアーゼ及びインヒビターを含んで成る媒体中でセリンプロテ アーゼインヒビターによりセリンプロテアーゼを阻害するための方法であって、 ここで前記インヒビターは、キレート化できる生理学的に許容する二価の金属カ チオンをキレート化するために相互に立体的な関係での2個のヘテロ原子を含ん で成り; 十分な量の二価の金属カチオンを有し、又は二価の金属カチオン錯体としてセ リンプロテアーゼに結合されるいづれかの又はすべてのインヒビターを有するよ うに媒体に十分な量の二価の金属カチオンを添加し、又は二価の金属カチオンが 二価の金属カチオンの三元錯体としてインヒビターとセリンブロテアーゼとの間 で結合されるように、二価の金属カチオン二元錯体としてインヒビターを供給す ることを含んで成る方法。 22.前記二価の金属カチオンが亜鉛である請求の範囲第21項記載の方法。 23.前記二価の金属カチオンがコバルトである請求の範囲第21項記載の方法。 24.前記2つのヘテロ原子が環の環内員である請求の範囲第21項記載の方法。 25.前記ヘテロ原子の少なくとも1つが、ベンズイミダゾール環 の環内員である請求の範囲第24項記載の方法。 26.前記インヒビターが亜鉛二元錯体として供給される請求の範囲第21項記載 の方法。 27.前記添加される亜鉛の量が、セリンプロテアーゼインヒビターの濃度に少 なくとも等しい濃度に媒体中の亜鉛濃度を変更するのに十分である請求の範囲第 21項記載の方法。 28.前記セリンプロテアーゼが、活性化されたプロテインC、チマーゼ、キモ トリブシン、サイトメガロウィルスプロテアーゼ、エラスターゼ、第VIIa因子 、第IXa因子、第Xa因子、血漿カリクレイン、組織カリクレイン、β−ラクタ マーゼ、プラスミン、トロンビン、トリプシン、トリプターゼ及びウロキナーゼ から成る群から選択される請求の範囲第21項記載の方法。 29.セリンプロテアーゼ及びインヒビターを含んで成る媒体中で、ビス(ベン ズイミダゾール)を含んで成るセリンプロテアーゼインヒビターによりセリンプ ロテアーゼを阻害するための方法であって、ここで前記インヒビターが亜鉛をキ レート化するために立体的関係で前記ビス(ベンズイミダゾール)の窒素原子を 含んで成り、 亜鉛二元錯体としてセリンプロテアーゼに結合されるインヒビターのすべてを 有するよう前記媒体に十分な亜鉛を添加し、又は亜鉛錯体として前記インヒビタ ーを供給することを含んで成る方法。 30.前記ビス(ベンズイミダゾール)がアミジノ基により置換される請求の範 囲第29項記載の方法。 31.前記セリンプロテアーゼが、活性化されたプロテインC、チマーゼ、キモ トリプシン、サイトメガロウィルスプロテアーゼ、エラスターゼ、第VIIa因子 、第IXa因子、第Xa因子、血漿カリクレイン、組織カリクレイン、β−ラクタ マーゼ、プラスミン、トロンビン、トリプシン、トリプターゼ及びウロキナーゼ から成る群から 選択される請求の範囲第29項記載の方法。 32.下記式I: {(BP)r-(I)}n(Y)q I 〔式中、 qは0でありそしてnは1であり、又はqは1でありそしてnは2であり; Yは結合、又は6個よりも多くない、典型的には3個よりも多くない原子そし て好ましくは鎖中の炭素原子の連結基であり; Bpはセリンプロテアーゼの1又は複数のP部位に結合するための連結成分で あり; rは0又は1であり、但し少なくとも1つのBp結合成分が存在し;そして Iは、nが2である場合、少なくとも1つのヘテロ原子を含んで成り、そして nが1である場合、少なくとも2個のヘテロ原子を含んで成る成分であり、ここ で2個のヘテロ原子は、二配座態様で二価の金属カチオンをキレート化できるよ う相互立体的関係で存在する〕 で表わされる化合物の二価の金属カチオン二元錯体。 33.請求の範囲第32項記載の二価の金属カチオン二元錯体及びセリンプロテア ーゼを含んで成る二価の金属カチオン三元錯体。 34.前記セリンプロテアーゼが、活性化されたプロテインC、チマーゼ、キモ トリプシン、サイトメガロウィルスプロテアーゼ、エラスターゼ、第VIIa因子 、第IXa因子、第Xa因子、血漿カリクレイン、組織カリクレイン、β−ラクタ マーゼ、プラスミン、トロンビン、トリプシン、トリプターゼ及びウロキナーゼ から成る群から選択される請求の範囲第33項記載の三元錯体。 32.下記式II: (BP)r{α-(A)-β} II 〔式中、Bpはセリンプロテアーゼの1つの又は複数のP部位を結合するための 連結成分であり; rは0又は1であり、但し、少なくとも1つのBp結合成分が存在し; Aは結合、又はアルキレン、ヘテロアルキレン、シクロアルキレン、アリーレ ン、及びヘテロアリーレンから選択された連結基であり、この連結基は、1〜2 個の原子によりα及びβを分離し、そして任意には、オキソ、ヒドロキシ、(C1-2 )アルキルオキシ、ハロ、メルカプト(C1-2)アルキルチオ、アミノ、(C1-2 )アルキルアミノ及びジ(C1-2)アルキルアミノから選択された1〜2個の 基により置換されていてもよく、ここでヘテロ原子が炭素又は水素のみに結合さ れ;そして α及びβはそれぞれ、独立して、2〜36個の炭素原子を含んで成る基であり、 そしてα及びβの個々内に含まれる少なくとも1つのヘテロ原子がAの3個の原 子内にあり、そして他のヘテロ原子の6個の原子内にあり、α及びβは任意には 、アルキレン及びヘテロアルキレンから選択された連結基を通して一緒に結合さ れていてもよく、前記基は任意には、オキソ、ヒドロキシ、(C1-2)アルキル オキシ、ハロ、メルカプト、(C1-2)アルキルチオ、アミノ、(C1-2)アルキ ルアミノ、及びジ(C1-2)アルキルアミノから選択された1〜2個の基により 置換されていてもよく、ここでヘテロ原子は、2個の関連するヘテロ原子が二価 の金属カチオンの二配座キレート化を促進するために相互立体的に関連して配置 されるような態様で、炭素又は水素のみに結合される〕で表わされる化合物の二 価の金属カチオン二元錯体。 36.前記α及びβは個々に、独立して、Aに直接的に又は間接的 に結合された、(C3-18)ヘテロシクロアルキルもしくは(C5-18)ヘテロアリ ール成分を含んで成る基、又はヘテロ原子含有成分により置換された、(C2-18 )アルキル、(C3-18)シクロアルキル、(C6-18)アリール、(C3-18)ヘテ ロシクロアルキルもしくは(C5-18)ヘテロアリール成分を含んで成る基であり 、ここでα及びβの個々内に含まれる少なくとも1つの環内又は非環内ヘテロ原 子がAの2個の原子内及び他のヘテロ原子の4個の原子内に存在する請求の範囲 第35項記載の錯体。 37.前記α及びβは個々に、独立して、Aに直接的に又は間接的に結合された 、(C3-12)ヘテロシクロアルキルもしくは(C5-12)ヘテロアリール成分を含 んで成る基、又はヘテロ原子含有成分により置換された、(C2-12)アルキル、 (C3-12)シクロアルキル、(C6-12)アリール、(C3-12)ヘテロシクロアル キルもしくは(C5-12)ヘテロアリール成分を含んで成る基であり、ここでα及 びβの個々内に含まれる少なくとも1つの環状又は非環状ヘテロ原子がAの1つ の原子内に存在する請求の範囲第36項記載の錯体。 38.前記二価の金属カチオンが亜鉛であり、α及びβはそれぞれベンズイミダ ゾリルであり、γは1であり、そしてBpは、塩基性窒素原子が炭素原子を通し てその5−位でα又はβに結合されている基を含んで成る請求の範囲第37項記載 の錯体。 39.前記Bpがアミノメチルである請求の範囲第38項記載の錯体。 40.前記Bpがアミジノである請求の範囲第38項記載の錯体。 41.セリンプロテアーゼと共に請求の範囲第35項記載の二元錯体を含んで成る 二価の金属カチオン三元錯体。 42.前記二価の金属カチオンが亜鉛である請求の範囲第41項記載の三元錯体。 43.前記αがベンズイミダゾール環である請求の範囲第42項記載の三元錯体。 44.前記ベンズイミダゾール環に結合されるBpがアミジノである請求の範囲 第43項記載の三元錯体。 45.前記セリンプロテアーゼインヒビターが2−(5−アミジノ)ベンズイミ ダゾール−2−イルメチルベンズイミダゾールである請求の範囲第44項記載の三 元錯体。 46.前記セリンプロテアーゼインヒビターが、2−(5−アミノメチル)ベン ズイミダゾール−2−イルメチル−5−メチルベンズイミダゾールである請求の 範囲第44項記載の三元錯体。 47.前記セリンプロテアーゼインヒビターが、2−(5−カルボキシ)ベンズ イミダゾール−2−イルメチルベンズイミダゾールである請求の範囲第44項記載 の三元錯体。 48.前記セリンプロテアーゼが、活性化されたプロテインC、チマーゼ、キモ トリプシン、サイトメガロウィルスプロテアーゼ、エラスターゼ、第VIIa因子 、第IXa因子、第Xa因子、血漿カリクレイン、組織カリクレイン、β−ラクタ マーゼ、プラスミン、トロンビン、トリプシン、トリプターゼ及びウロキナーゼ から成る群から選択される請求の範囲第41項記載の三元錯体。 49.下記式III: (BP){Xa-(γ)-Xb} III 〔式中、Bpはセリンプロテアーゼの1又は複数のP部位を結合するための結合 成分であり; γは6〜18個の炭素原子を含んで成る、芳香族又は非芳香族、飽和又は不飽和 の融合された多環式炭化水素であり;そして Xa及びXbは独立して、γ内に含まれる環状ヘテロ原子、又はγに直接的に結 合された、ヘテロ原子含有成分であり、ここでXa 及びXbはお互いの6個の原子、典型的には4個の原子内にある〕 で表わされる化合物の二価の金属カチオン二元錯体。 50.セリンプロテアーゼと共に請求の範囲第49項記載の二元錯体を含んで成る 二価の金属カチオン四元錯体。 51.前記セリンプロテアーゼが、活性化されたプロテインC、チマーゼ、キモ トリプシン、サイトメガロウィルスプロテアーゼ、エラスターゼ、第VIIa因子 、第IXa因子、第Xa因子、血漿カリクレイン、組織カリクレイン、β−ラクタ マーゼ、プラスミン、トロンビン、トリプシン、トリプターゼ及びウロキナーゼ から成る群から選択される請求の範囲第50項記載の四元錯体。 52.請求の範囲第1項記載の方法により同定されるセリンプロテアーゼインヒ ビター。 53.前記セリンプロテアーゼが、活性化されたプロテインC、チマーゼ、キモ トリプシン、サイトメガロウィルスプロテアーゼ、エラスターゼ、第VIIa因子 、第IXa因子、第Xa因子、血漿カリクレイン、組織カリクレイン、β−ラクタ マーゼ、プラスミン、トロンビン、トリプシン、トリプターゼ及びウロキナーゼ から成る群から選択される請求の範囲第51項記載のセリンプロテアーゼインヒビ ター。 54.セリンプロテアーゼ活性が疾病の病理学及び/又は症候学に寄与する、動 物における疾病の処理方法であって、請求の範囲第1項記載の方法により同定さ れるセリンプロテアーゼインヒビターの治療的有効量を前記動物に投与すること を含んで成る方法。 55.前記セリンプロテアーゼが、活性化されたプロテインC、チマーゼ、キモ トリプシン、サイトメガロウィルスプロテアーゼ、エラスターゼ、第VIIa因子 、第IXa因子、第Xa因子、血漿カリクレイン、組織カリクレイン、β−ラクタ マーゼ、プラスミン、トロン ビン、トリプシン、トリプターゼ及びウロキナーゼから成る群から選択される請 求の範囲第53項記載の方法。 56.セリンプロテアーゼ活性が疾病の病理学及び/又は症候学に寄与する、動 物における疾病の処理方法であって、請求の範囲第31項記載の錯体の治療的有効 量を前記動物に投与することを含んで成る方法。 57.前記セリンプロテアーゼが、活性化されたプロテインC、チマーゼ、キモ トリプシン、サイトメガロウィルスプロテアーゼ、エラスターゼ、第VIIa因子 、第IXa因子、第Xa因子、血漿カリクレイン、組織カリクレイン、β−ラクタ マーゼ、プラスミン、トロンビン、トリプシン、トリプターゼ及びウロキナーゼ から成る群から選択される請求の範囲第56項記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/746,986 US6255091B1 (en) | 1995-04-28 | 1996-11-19 | Potentiating metal mediated serine protease inhibitors with cobalt or zinc ions |
US08/746,986 | 1996-11-19 | ||
PCT/US1997/004450 WO1998022619A1 (en) | 1996-11-19 | 1997-03-21 | Metal mediated serine protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2002516566A true JP2002516566A (ja) | 2002-06-04 |
Family
ID=25003190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52360898A Ceased JP2002516566A (ja) | 1996-11-19 | 1997-03-21 | 金属介在セリンプロテアーゼインヒビター |
Country Status (7)
Country | Link |
---|---|
US (2) | US6255091B1 (ja) |
EP (1) | EP0943008B1 (ja) |
JP (1) | JP2002516566A (ja) |
AT (1) | ATE309386T1 (ja) |
AU (1) | AU2336497A (ja) |
DE (1) | DE69734597D1 (ja) |
WO (1) | WO1998022619A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8394372B2 (en) | 2004-09-21 | 2013-03-12 | Trobio Ab | Stabilized protease composition |
JP2014505690A (ja) * | 2011-01-11 | 2014-03-06 | スノビオン プハルマセウトイカルス インコーポレイテッド | ヘテロアリール化合物及びその使用方法 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6150379A (en) * | 1997-11-26 | 2000-11-21 | Axys Pharmaceuticals, Inc. | Compounds and compositions as anticoagulants |
CZ20012006A3 (cs) | 1998-12-18 | 2002-03-13 | Axys Pharmaceuticals, Inc. | Sloučenina a farmaceutický prostředek |
WO2000051624A2 (en) | 1999-03-05 | 2000-09-08 | The Trustees Of University Technology Corporation | Methods and compositions useful in inhibiting apoptosis |
AU3194900A (en) * | 1999-03-19 | 2000-10-09 | Yamanouchi Pharmaceutical Co., Ltd. | Method for screening cysteine protease inhibitor |
US20040072862A1 (en) * | 1999-06-04 | 2004-04-15 | Bitler Catherine M. | Compositions for treating ischemia-related neuronal damage |
DE60007310D1 (de) | 1999-06-04 | 2004-01-29 | Elan Pharma Int Ltd | Zusammensetzungen und methoden zur verhinderung des zelltods |
IL140994A (en) * | 2000-05-15 | 2005-12-18 | Bayer Ag | Urinary trypsin inhibitor assay containing a chelating agent |
AU2002364185A1 (en) * | 2001-12-21 | 2003-07-30 | Immunochemistry Technologies, Llc | Affinity labeling of serine proteases for simultaneous detection of multiple serine protease activity levels |
AU2002351756A1 (en) | 2001-12-21 | 2003-07-15 | Novo Nordisk Health Care Ag | Liquid composition of factor vii polypeptides |
CA2490342C (en) | 2002-06-21 | 2015-06-16 | Novo Nordisk A/S | Stabilised solid compositions of factor vii polypeptides |
AU2003259261B2 (en) * | 2002-07-30 | 2005-11-24 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Use of chymase inhibitors for the prevention and/or treatment of arterio-venous graft failure |
US7897734B2 (en) | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
WO2004112828A1 (en) | 2003-06-25 | 2004-12-29 | Novo Nordisk Health Care Ag | Liquid composition of factor vii polypeptides |
ES2574581T3 (es) | 2003-08-14 | 2016-06-20 | Novo Nordisk Health Care Ag | Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII |
JP2007504144A (ja) | 2003-08-26 | 2007-03-01 | ザ リージェンツ オブ ザ ユニバーシティー オブ コロラド ア ボディー コーポレイト | セリンプロテアーゼ活性阻害因子、ならびに細菌感染の治療法および組成物におけるその使用方法 |
RU2462762C1 (ru) * | 2011-07-08 | 2012-09-27 | Государственное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации | Способ моделирования хронической токсической артериальной гипертонии и кардиопатии у экспериментальных животных |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3646049A (en) | 1970-03-05 | 1972-02-29 | Merck & Co Inc | Acylaminobenzimidazole derivatives |
SU833304A1 (ru) * | 1979-11-19 | 1981-05-30 | Институт Химии Нефти И Природныхсолей Ah Казахской Ccp | Катализатор дл окислени н- гЕКСАдЕКАНА |
HU188916B (en) | 1983-06-30 | 1986-05-28 | Budapesti Vegyimuevek,Hu | Sinergetic fungicide compositions for cereals containing derivatives of carbamide acid and ditiocarbamate |
AU604542B2 (en) * | 1987-03-19 | 1990-12-20 | Arthropharm Pty Ltd | Polysulphated polysaccharide complexes |
GB8711391D0 (en) | 1987-05-14 | 1987-06-17 | Beecham Group Plc | Process |
US4935493A (en) | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
US4940723A (en) | 1988-10-20 | 1990-07-10 | University Of North Carolina, Chapel Hill | Use of bis-(5-amidino-2-benzimidazolyl) methane (BABIM) to treat arthritis |
JPH09506335A (ja) | 1993-09-22 | 1997-06-24 | ザ、ウェルカム、ファンデーション、リミテッド | 抗ウイルス剤としてのビス(アミノベンズイミダゾリル)アルカン |
AU1186295A (en) | 1993-11-24 | 1995-06-13 | University Of Washington | Blood coagulation retardants and devices |
US6815461B1 (en) | 1994-01-20 | 2004-11-09 | The University Of North Carolina At Chapel Hill | Method of inhibiting retroviral integrase |
EP0777656B1 (en) | 1994-08-26 | 2004-04-14 | Auckland Division Cancer Society Of New Zealand (Incorporated) | Novel dna-targeted alkylating agents |
US6008190A (en) | 1994-12-15 | 1999-12-28 | California Institute Of Technology | Cobalt Schiff base compounds |
US5693515A (en) * | 1995-04-28 | 1997-12-02 | Arris Pharmaceutical Corporation | Metal complexed serine protease inhibitors |
-
1996
- 1996-11-19 US US08/746,986 patent/US6255091B1/en not_active Expired - Fee Related
-
1997
- 1997-03-21 JP JP52360898A patent/JP2002516566A/ja not_active Ceased
- 1997-03-21 DE DE69734597T patent/DE69734597D1/de not_active Expired - Lifetime
- 1997-03-21 AU AU23364/97A patent/AU2336497A/en not_active Abandoned
- 1997-03-21 AT AT97916103T patent/ATE309386T1/de not_active IP Right Cessation
- 1997-03-21 WO PCT/US1997/004450 patent/WO1998022619A1/en active IP Right Grant
- 1997-03-21 EP EP97916103A patent/EP0943008B1/en not_active Expired - Lifetime
-
1999
- 1999-07-12 US US09/351,869 patent/US6355460B1/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8394372B2 (en) | 2004-09-21 | 2013-03-12 | Trobio Ab | Stabilized protease composition |
US8574569B2 (en) | 2004-09-21 | 2013-11-05 | Trobio Ab | Stabilized protease composition |
JP2014505690A (ja) * | 2011-01-11 | 2014-03-06 | スノビオン プハルマセウトイカルス インコーポレイテッド | ヘテロアリール化合物及びその使用方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2336497A (en) | 1998-06-10 |
EP0943008B1 (en) | 2005-11-09 |
WO1998022619A1 (en) | 1998-05-28 |
US6255091B1 (en) | 2001-07-03 |
ATE309386T1 (de) | 2005-11-15 |
DE69734597D1 (de) | 2005-12-15 |
US6355460B1 (en) | 2002-03-12 |
EP0943008A1 (en) | 1999-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002516566A (ja) | 金属介在セリンプロテアーゼインヒビター | |
EP1012166B1 (en) | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | |
Alterman et al. | Design and synthesis of new potent C 2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold | |
AU698705B2 (en) | Thrombin inhibitors | |
US5750520A (en) | Antithrombotic amidinophenylalanine and amidinopyridylalanine derivatives | |
EP4178955A1 (en) | Antiviral heteroaryl ketone derivatives | |
US5693515A (en) | Metal complexed serine protease inhibitors | |
JPH10512300A (ja) | カテプシンkの阻害法 | |
US5798352A (en) | Antithrombotic amidinotetrahydropyridylalanine derivatives | |
JP4653100B2 (ja) | N−スルホニル化アミノ酸誘導体およびマトリプターゼ阻害剤としてのそれらの使用 | |
US4873253A (en) | Phenylalanine derivative and proteinase inhibitor | |
US6124291A (en) | Pyrrolo[1,2-a]pyrazine-1,4-dione serine protease inhibitors | |
Mohamed et al. | Synthesis and human/bacterial carbonic anhydrase inhibition with a series of sulfonamides incorporating phthalimido moieties | |
WO2007038772A1 (en) | Novel drugs for dementia | |
US6642253B2 (en) | Thrombin inhibitors comprising an aminoisoquinoline group | |
STÜRZEBECHER et al. | Interactions of thrombin with benzamidine-based inhibitors | |
Peterlin-Mašic̆ et al. | Novel thrombin inhibitors incorporating non-basic partially saturated heterobicyclic P1-Arginine mimetics | |
Salimbeni et al. | Design and synthesis of conformationally constrained arginal thrombin inhibitors | |
Sperl et al. | Urethanyl-3-amidinophenylalanine derivatives as inhibitors of factor Xa. X-ray crystal structure of a trypsin/inhibitor complex and modeling studies | |
Girnys et al. | Conformationally restricted analogs of the direct thrombin inhibitor FM 19 | |
D'Alessio et al. | Conformationally constrained analogues of endogenous tripeptide inhibitors of zinc metalloproteinases | |
CZ381297A3 (cs) | Imidazo /1,5a/ pyridinové deriváty a farmaceutický prostředek s jejich obsahem | |
AU713527B2 (en) | Thrombin inhibitors | |
Murphy et al. | Synthesis and anticancer activity of asparagine analogs | |
JPS61130268A (ja) | リジン誘導体及び抗プラスミン剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040316 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050208 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20050128 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050506 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050620 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050808 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050927 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20060213 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060328 |